SCHEMBL1008012

SCHEMBL1008012

Cc1cccc(C)c1COc1cc(CC#N)ccc1F

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 4/20 0.50
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.37
HTR6 P50406 2/20 0.36
MMP3 P08254 1/20 0.35
ENPP2 Q13822 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SGMS2 Q8NHU3 2/20 0.34
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
ANO1 Q5XXA6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1234544 0.89 SLC22A12 (0.62) SLC22A12CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL1234546 0.84 SLC22A12 (0.56) SLC22A12CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL13568832 0.83 SLC22A12 (0.51) SLC22A12CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL1062655 0.82 SLC22A12 (0.50) SLC22A12CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL1009161 0.82 SLC22A12 (0.53) SLC22A12CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL956632 0.77 SLC22A12 (0.78) SLC22A12MRGPRX4
SCHEMBL1235319 0.77 SLC22A12 (0.52) SLC22A12MRGPRX4MMP3ENPP2MAOB
SCHEMBL3905475 0.76 CYP4F2 (0.36) ENPP2NPC1RAB9A
SCHEMBL30641472 0.75 CA2 (0.41) NPC1RAB9A
SCHEMBL622290 0.75 CA2 (0.41) NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 SLC22A12 139/4885CYP3A4 2337/4885CYP2C9 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.